Clinical trials of HIV vaccines

Annual Review of Medicine

Volumn 53, Issue , 2002, Pages 207-221

  Graham, Barney S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

AIDS; Cytotoxic T lymphocyte; Immunity; Neutralizing antibody; Virus

Indexed keywords

CD8 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; DNA VACCINE; GAMMA INTERFERON; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RECOMBINANT VACCINE;

ANTIBODY RESPONSE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG ANTIGENICITY; DRUG DESIGN; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOMODULATION; INFECTION CONTROL; INFECTION PREVENTION; PRIORITY JOURNAL; REVIEW; VACCINATION; VACCINE PRODUCTION; VIRUS INHIBITION; VIRUS TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; CLINICAL TRIALS; DISEASE OUTBREAKS; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; T-LYMPHOCYTES;

EID: 0036181247     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.53.082901.104035     Document Type: Review

References (74)

1. Improbability of effective vaccination against human immunodeficiency virus because of its intracellular transmission and rectal portal of entry
2. The challenge of viral reservoirs in HIV-1 infection
3. Human ecology and behavior and sexually transmitted bacterial infections
4. Viral load and heterosexual transmission of human immunodeficiency virus type 1
5. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda
6. Incidence and prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and cytomegalovirus among health care personnel at risk for blood exposure: Final report from a longitudinal study
7. Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants
8. HIV-1 genomic RNA diversification following sexual and parenteral virus transmission
9. Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya
10. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women
11. Molecular and functional analysis of a conserved CTL epitope in HIV-1 p24 recognized from a long-term nonprogressor: Constraints on immune escape associated with targeting a sequence essential for viral replication
12. In vitro correlates of HIV-2 mediated HIV-1 protection
13. Immunologic control of HIV-1
14. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
15. Modern vaccines: The immunological principles of vaccination
16. CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication
17. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells
18. The antiviral activity of antibodies in vitro and in vivo
19. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage
20. Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage
21. Analysis of host-virus interactions in AIDS with anti-gp120 T cell clones: Effect of HIV sequence variation and a mechanism for CD4+ cell depletion
22. Viral persistence: HIV's strategies of immune system evasion
23. Prevention of HIV infection by passive immunization with HIV immunoglobulin
24. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody
25. sm infection by passive immunization in cynomolgus monkeys
26. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys
27. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
28. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
29. Anti-cell antibody in macaques
30. Preliminary report: Protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected-cell vaccine
31. Detection of anti-human cell antibodies in sera from macaques immunized with whole inactivated virus
32. Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection
33. Passive immune globulin therapy in the SIV/macaque model: Early intervention can alter disease profile
34. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
35. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
36. Escape of human immunodeficiency virus from immune control
37. HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood
38. ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids
39. Genomic structure of an attenuated quasi species of HIV-1 from blood transfusion donor recipients
40. Brief report: Absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection
41. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection
42. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
43. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy
44. Immune control of HIV-1 after early treatment of acute infection
45. Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques
46. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: Effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara
47. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV
48. CD8 T cell anti-HIV activity as a complementary protective mechanism in vaccinated chimpanzees
49. Introduction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen
50. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge
51. Long-term survival of SIVmac251-infected macaques previously immunized with NYVAC-SIV vaccines
52. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles
53. Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection
54. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
55. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
56. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine
57. AIDS vaccine development
58. Clinical trials of HIV vaccines
59. Safety profile of phase I and II preventive HIV-1 vaccination: Experience of the AIDS Vaccine Evaluation Group
60. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults
61. Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand
62. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein
63. Cytotoxic T cell and neutralizing antibody responses to HIV-1 envelope with a combination vaccine regimen
64. Comparative clonal analysis of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines
65. Persisting human immunodeficiency virus type 1 gp160-specific human T lymphocyte responses including CD8+ cytotoxic activity after receipt of envelope vaccines
66. HIV-1 immune responses induced by canarypox (ALVAC)-gp160 MN, SF-2 rgp120, or both vaccines in seronegative adults
67. A canarypox vaccine expressing multiple HIV-1 genes given alone or with rgp120 elicits broad and durable CD8+ CTL responses in seronegative volunteers
68. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers
69. Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection
70. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus type 1 vaccine with or without gp120: A phase 2 study in higher- and lower-risk volunteers
71. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers
72. Resistance to human immunodeficiency virus type 1 in vitro as a surrogate of vaccine-induced protective immunity
73. Counting antigen-specific CD8 T cells: A reevaluation of bystander activation during viral infection